Invention Grant
- Patent Title: Compositions for modulating expression of C9ORF72 antisense transcript
-
Application No.: US15540251Application Date: 2016-01-06
-
Publication No.: US10793855B2Publication Date: 2020-10-06
- Inventor: Frank Rigo
- Applicant: Ionis Pharmaceuticals, Inc.
- Applicant Address: US CA Carlsbad
- Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee: Ionis Pharmaceuticals, Inc.
- Current Assignee Address: US CA Carlsbad
- Agency: McNeill Baur PLLC
- International Application: PCT/US2016/012381 WO 20160106
- International Announcement: WO2016/112132 WO 20160714
- Main IPC: C07H21/04
- IPC: C07H21/04 ; C12N15/113 ; A61K45/06 ; A61K31/7125 ; A61K31/712 ; A61K9/00 ; A61K31/713
Abstract:
Disclosed herein are compositions and methods for reducing expression of C9ORF72 antisense transcript in an animal with C9ORF72 antisense transcript specific inhibitors. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Such C9ORF72 antisense transcript specific inhibitors include antisense compounds.
Public/Granted literature
- US20180023077A1 COMPOSITIONS FOR MODULATING EXPRESSION OF C9ORF72 ANTISENSE TRANSCRIPT Public/Granted day:2018-01-25
Information query
